FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's CancerA2A PharmaMay 22, 20230 min read
A2A TACC3 Program Clinical Progress in Womens CancersMay 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st...
A2A co-founded biomea Fusion raises $56MBiomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...
A2A / Daewoong Pharmaceutical Oncology Agreement A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology...
Comments